消息

Earnings beats have continued: Q4 EPS exceeded expectations by 22 %. Full‑year EPS estimates have risen 18.09 % in the past 60 days, with a Zacks Consensus Estimate of $8.16 per share, implying nearly 30 % growth relative to the prior year. FY26 earnings are now projected to spike 29 % to $8.16 per share, and FY27 EPS is forecast to climb another 1...

全文

Financially, Hershey’s salty‑snacks segment grew 28 % year‑over‑year in Q4, generating $357 million. Annual sales are projected to rise 5 % this year and another 2 % in fiscal 2027 to $12.54 billion. The company’s cash position has surged, with cash and equivalents reaching $926 million—an 181 % increase from $329 million at the end of 2021.

全文

Hershey’s announced a March 12 launch of a limited‑quantity Twizzlers Straws flavor, blending vanilla, lime and coconut notes for $4.49 at shop.hersheys.com, Gopuff and select Hershey’s Chocolate World locations. The new product is positioned to tap the “dirty soda” trend, allowing consumers to sip, snack and customize drinks with a single edible s...

全文

Omda’s fair‑value target remains at NOK 59.0, underscoring a stable valuation anchor despite recent model tweaks. Analysts highlighted the company’s strong Q4 performance, citing an 8 % revenue beat and a $7 m EBITDA beat, while noting that valuation pressure in the Healthcare Information Technology sector and client concentration could temper upsi...

全文

Quantum Blockchain Technologies PLC’s CEO, Francesco Gardin, announced that the company has received its first bitcoin‑mining rig, which is currently being tested in Oregon. After confirming that the rig meets specifications, it will be shipped to Milan where QBT will integrate its Method C AI Oracle software with the ASIC mining hardware. The Meth...

全文

Goldman Sachs Group, Inc. disclosed its Ontex Group NV holdings under Belgian law. On 26 February 2025, the investment bank owned 358,662 voting rights and 2,463,332 equivalent financial instruments, amounting to 3.43 % of Ontex’s issued shares – a level that crossed the 3 % threshold for equivalent financial instruments, signalling heightened infl...

全文

Collectively, the data show TG Therapeutics heavily reliant on BRIUMVI’s U.S. sales, a strategic pivot toward subcutaneous delivery, and an emerging but still nascent cell‑therapy pipeline. The company’s financials, valuation metrics, and forthcoming product launches continue to shape investor expectations and market valuation.

全文

Revenue and earnings forecasts diverge. Some projections anticipate $1.2 billion in revenue and $469 million in earnings by 2028, while others assume $1.0 billion in revenue and $344.7 million in earnings. These disparities highlight uncertainty around payer pushback, competition, and the pace of azer‑cel progress.

全文

Capital‑market sentiment reflects this strategic focus. Bank of America reaffirmed a Sell rating with a $15 price target, citing a 49 % downside from current levels. Despite a 24 % decline in total shareholder return, the three‑year return has more than doubled, and analysts maintain an intrinsic value of $132.02 per share against a market price of...

全文

The company’s 2025 earnings release underscored the centrality of BRIUMVI, noting the drug’s proven efficacy in reducing relapse and MRI activity in highly active relapsing multiple sclerosis. A clinical milestone for azercabtagene zapreleucel (azer‑cel) in progressive MS, which generated a $7.5 million payment from Precision BioSciences, marked th...

全文